← Evidence map

ArticlePharmacoEconomics - open2022

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.

Rachel Milstein Breslau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates. | OpenQuestion